The new test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, detects amyloid plaques through blood testing, a ...

The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...

The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA has approved the Lumipulse Plasma Ratio test, a groundbreaking blood test for early dementia detection. This less ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance ...

The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in ...

The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood test for early Alzheimer's ...

There's a new way to screen for early detection of Alzheimer's disease. On Friday, the Food and Drug Administration (FDA) ...

The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in symptomatic adults 55 years and older.